Senti Biosciences Enters Material Definitive Agreement
Ticker: SNTI · Form: 8-K · Filed: Sep 27, 2024 · CIK: 1854270
Sentiment: neutral
Topics: material-definitive-agreement
TL;DR
Senti Bio signed a big deal, details TBD.
AI Summary
On September 23, 2024, Senti Biosciences, Inc. entered into a Material Definitive Agreement. The filing does not disclose specific details of the agreement or any associated dollar amounts or parties involved.
Why It Matters
This filing indicates a significant new agreement for Senti Biosciences, which could impact its future operations and strategic direction.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the material definitive agreement.
Key Players & Entities
- Senti Biosciences, Inc. (company) — Registrant
- September 23, 2024 (date) — Date of earliest event reported
- September 27, 2024 (date) — Date of Report
FAQ
What is the nature of the Material Definitive Agreement entered into by Senti Biosciences, Inc.?
The filing does not specify the nature of the Material Definitive Agreement.
Who are the other parties involved in this Material Definitive Agreement?
The filing does not disclose the names of the other parties to the agreement.
What is the effective date of this Material Definitive Agreement?
The earliest event reported is September 23, 2024.
Are there any financial implications or dollar amounts associated with this agreement?
The filing does not provide any information regarding dollar amounts or financial implications of the agreement.
Where is Senti Biosciences, Inc. headquartered?
Senti Biosciences, Inc. is headquartered at 2 Corporate Drive, First Floor, South San Francisco, California 94080.
Filing Stats: 606 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2024-09-27 16:42:14
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SNTI The Nasdaq Capital Marke
- $35,147.95 — hly base rent the Subtenant will pay is $35,147.95 per month for the first year of the sub
- $36,378.13 — ear of the sublease term, increasing to $36,378.13 per month for the second year of the su
- $37,651.36 — of the sublease term, and increasing to $37,651.36 per month for the third year of the sub
Filing Documents
- snti-20240923.htm (8-K) — 26KB
- 0001854270-24-000105.txt ( ) — 150KB
- snti-20240923.xsd (EX-101.SCH) — 2KB
- snti-20240923_lab.xml (EX-101.LAB) — 22KB
- snti-20240923_pre.xml (EX-101.PRE) — 13KB
- snti-20240923_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On September 23, 2024, Senti Biosciences, Inc. (the "Company"), as the sublandlord, entered into a sublease agreement, or the Sublease, with BKPBIOTECH, Inc., a Delaware corporation and JLSA2 Therapeutics, Inc., a Delaware corporation (jointly and severally, the "Subtenant") for approximately 7,247 rentable square feet (the "RSF") of certain space located on a portion of the first floor of the Company's corporate headquarters, Two Corporate Drive, First Floor, South San Francisco, CA 94080. The term of the Sublease is estimated to be effective on October 1, 2024, subject to the consent by the landlord, Britannia Biotech Gateway Limited Partnership and will expire April 30, 2027, subject to earlier termination in accordance with the terms of the Sublease. The initial monthly base rent the Subtenant will pay is $35,147.95 per month for the first year of the sublease term, increasing to $36,378.13 per month for the second year of the sublease term, and increasing to $37,651.36 per month for the third year of the sublease term. The Sublease contains customary events of default, representations, warranties and covenants. The foregoing description of the Sublease does not purport to be a complete description of the rights and obligations of the parties thereunder, and is qualified in its entirety by reference to the full text of the Sublease, which the Company expects to file as an exhibit to its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SENTI BIOSCIENCES, INC. Date: September 27, 2024 By: /s/ Timothy Lu Name: Timothy Lu Title: Chief Executive Officer